Surabhi Dangi-Garimella, PhD, Managing Editor, Evidence-Based Oncology

A proposal to reduce Medicare Part B payment rates for hospitals participating in the 340B Drug Pricing Program has been approved 14-3 by the Medicare Payment Advisory Commission.

A proposal to reduce Medicare Part B payment rates for hospitals participating in the 340B Drug Pricing Program has been approved 14-3 by the Medicare Payment Advisory Commission.

A new study conducted by researchers at Kaiser Permanente has found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

After having launched a palliative care program in 2014, Cambia Health Solutions is now looking for ways to improve patient access to these tools that can improve a patient's quality of life.

The FDA launcheda cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.

A new report by the Berkeley Research Group provides numbers on Medicare Part B spending by 340B entities, especially for oncology drugs.

Study finds researchers were either late or failed to report clinical trial results 95% of the time.

A new report by the Berkeley Research Group provides numbers on Medicare Part B spending by 340B entities, especially for oncology drugs.

A report by STAT has found that a majority of institutions conducting clinical trials fail to report their results to the web site ClinicalTrials.gov.

Experts provide unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma.

Researchers confirm antidepressants do not cause recurrence in breast cancer patients treated with tamoxifen.